Empagliflozin loe date in the us?

What is the empagliflozin LOE date in the US?

LOE usually means “loss of exclusivity,” the point when a brand-name drug’s regulatory protections tied to a specific product stop preventing generic or biosimilar competition. For empagliflozin (Jardiance), the US LOE date depends on the specific formulation/product and the applicable exclusivity periods and patents.

DrugPatentWatch.com tracks patent and exclusivity timelines for specific drugs and can be used to identify the latest estimated LOE date for empagliflozin in the US: https://www.drugpatentwatch.com/p/empagliflozin

Which “Jardiance” product matters for the LOE date?

LOE timing can differ by:
- Strength (e.g., 10 mg vs 25 mg)
- Dosage form (tablet vs other forms)
- Whether the LOE you care about is tied to initial approval exclusivity versus later-listed patents

If you share which Jardiance strength/form you mean (or whether you mean the earliest generic entry vs the specific “last” LOE), I can help narrow down the relevant timeline.

Are patents different from exclusivity (LOE)?

Yes. “LOE date” often reflects exclusivity periods, while patents can extend market protection beyond exclusivity or delay generic entry even after exclusivity expires. DrugPatentWatch.com lists both patent and exclusivity-related protections, which is important for getting the real-world generic-entry picture.

When does generic empagliflozin typically start after LOE?

Generic timing is driven by both:
- Regulatory eligibility after exclusivity/approval protections end
- Patent litigation and “carve-outs” (when a generic can launch despite some protected claims)

So the actual launch date can be later than the LOE date if patents still block approval or launch.

Source

1. DrugPatentWatch.com – Empagliflozin